

Product Update

colecalciferol 800 international units (equivalent to 20 micrograms vitamin D₃) tablets (Desunin 800 IU®) (No: 840/13)

Meda

11 January 2013

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

colecalciferol tablets (Desunin 800 IU®) is accepted for use within NHS Scotland.

Indication under review: prevention and treatment of vitamin D deficiency in adults and adolescents. In addition to specific osteoporosis treatment of patients who are at risk of vitamin D deficiency, supplemental calcium should be considered.

The therapeutic use and safety profile of colecalciferol as a treatment for vitamin D deficiency and as an adjunctive treatment in osteoporosis is well established. There are no comparative data for colecalciferol (Desunin®). It is the same cost as another vitamin D preparation.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 11 December 2012.

Chairman
Scottish Medicines Consortium